A. Menzies, G. Long, and R. Murali, Dabrafenib and its potential for the treatment of metastatic melanoma, Drug Des Devel Ther, vol.6, pp.391-405, 2012.

H. Davies, G. Bignell, and C. Cox, Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-954, 2002.
DOI : 10.1016/S0960-9822(97)70094-0

L. Boussemart, E. Routier, and C. Mateus, Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients, Annals of Oncology, vol.13, issue.8, pp.1691-1697, 2013.
DOI : 10.1016/S1470-2045(12)70269-3

M. Lacouture, M. Duvic, and A. Hauschild, Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma, The Oncologist, vol.18, issue.3, pp.314-322, 2013.
DOI : 10.1634/theoncologist.2012-0333

K. Flaherty, I. Puzanov, and K. Kim, Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-819, 2010.
DOI : 10.1056/NEJMoa1002011

G. Mcarthur, P. Chapman, and C. Robert, Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, The Lancet Oncology, vol.15, issue.3, pp.323-332, 2014.
DOI : 10.1016/S1470-2045(14)70012-9

J. Larkin, D. Vecchio, M. Ascierto, and P. , Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study, The Lancet Oncology, vol.15, issue.4, pp.436-444, 2014.
DOI : 10.1016/S1470-2045(14)70051-8

J. Sosman, K. Kim, and L. Schuchter, Survival in BRAF V600???Mutant Advanced Melanoma Treated with Vemurafenib, New England Journal of Medicine, vol.366, issue.8, pp.707-714, 2012.
DOI : 10.1056/NEJMoa1112302

S. Chandrakumar and J. Yeung, Cutaneous Adverse Events during Vemurafenib Therapy, Journal of Cutaneous Medicine and Surgery, vol.30, issue.4, pp.223-228, 2014.
DOI : 10.1007/s40265-013-0049-8

R. Dias, S. Salmonson, T. Van-zwieten-boot, and B. , The European Medicines Agency review of vemurafenib (Zelboraf??) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use, European Journal of Cancer, vol.49, issue.7, pp.1654-1661, 2013.
DOI : 10.1016/j.ejca.2013.01.015

E. Chu, K. Wanat, and C. Miller, Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study, Journal of the American Academy of Dermatology, vol.67, issue.6, pp.1265-1272, 2012.
DOI : 10.1016/j.jaad.2012.04.008

R. Dummer, S. Goldinger, and C. Turtschi, Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study, European Journal of Cancer, vol.50, issue.3, pp.611-621, 2014.
DOI : 10.1016/j.ejca.2013.11.002

P. Fava, E. Marra, and C. Astrua, Dermatological approach to vemurafenib skin toxicity: a single centre experience, G Ital Dermatol Venereol, 2014.

P. Mattei, M. Alora-palli, S. Kraft, D. Lawrence, K. Flaherty et al., Cutaneous effects of BRAF inhibitor therapy: a case series, Annals of Oncology, vol.29, issue.5, pp.530-537, 2013.
DOI : 10.1007/s10637-010-9567-3

J. Rinderknecht, S. Goldinger, and S. Rozati, RASopathic Skin Eruptions during Vemurafenib Therapy, PLoS ONE, vol.167, issue.5, p.58721, 2013.
DOI : 10.1371/journal.pone.0058721.g012

L. Vanneste, P. Wolter, J. Van-den-oord, M. Stas, and M. Garmyn, Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients., Journal of the European Academy of Dermatology and Venereology, vol.30, issue.1, pp.61-68, 2015.
DOI : 10.1200/JCO.2011.41.1660

E. Regnier-rosencher, H. Lazareth, L. Gressier, M. Avril, E. Thervet et al., Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas, British Journal of Dermatology, vol.21, issue.4, pp.934-938, 2013.
DOI : 10.1093/annonc/mdp472

K. Wenk, D. Pichard, T. Nasabzadeh, S. Jang, S. Venna et al., Vemurafenib-Induced DRESS, JAMA Dermatology, vol.149, issue.10, pp.1242-1243, 2013.
DOI : 10.1001/jamadermatol.2013.5278

URL : http://archderm.jamanetwork.com/data/journals/derm/928256/dlo130030.pdf

M. Wantz, I. Spanoudi-kitrimi, A. Lasek, D. Lebas, J. Quinchon et al., N??crolyse ??pidermique toxique au vemurafenib, Annales de Dermatologie et de V??n??r??ologie, vol.141, issue.3, pp.215-218, 2014.
DOI : 10.1016/j.annder.2013.10.054

R. Sinha, K. Lecamwasam, K. Purshouse, J. Reed, M. Middleton et al., Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma, British Journal of Dermatology, vol.69, issue.4, pp.997-999, 2014.
DOI : 10.1016/j.jaad.2013.05.002

R. Sinha, K. Edmonds, J. Newton-bishop, M. Gore, J. Larkin et al., Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities, British Journal of Dermatology, vol.30, issue.Suppl., pp.987-994, 2012.
DOI : 10.1200/JCO.2011.41.1660

A. Gey, B. Milpied, and C. Dutriaux, Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?, Journal of the European Academy of Dermatology and Venereology, vol.30, issue.1, 2014.
DOI : 10.1111/jdv.12685

G. Jeudy, S. Dalac-rat, and B. Bonniaud, Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis, British Journal of Dermatology, vol.149, issue.5, pp.1454-1455, 2015.
DOI : 10.1111/jdv.12685

A. Menzies, R. Kefford, and G. Long, Paradoxical oncogenesis: are all BRAF inhibitors equal?, Pigment Cell & Melanoma Research, vol.30, issue.5, pp.611-615, 2013.
DOI : 10.1200/JCO.2011.41.1660

T. Bellon and M. Blanca, The innate immune system in delayed cutaneous allergic reactions to medications, Current Opinion in Allergy and Clinical Immunology, vol.11, issue.4, pp.292-298, 2011.
DOI : 10.1097/ACI.0b013e3283489c2c

M. Peeters, S. Siena, and E. Van-cutsem, status in patients receiving panitumumab monotherapy, Cancer, vol.25, issue.7, pp.1544-1554, 2009.
DOI : 10.1007/978-94-017-0233-1